Comparative Efficacy, Safety, and Cost of Different Intrapleural Fibrinolytic Agents for the Management of Empyema Thoracis in Children: A Systematic Review.

Indian PediatrAug 19, 2026 (epub)
Clinical ResearchPediatricsPulmonologyOpen access

Meenakshi Malik, Sonia Bhatt, Sarika Gupta et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review aimed to evaluate the efficacy, safety, and cost of intrapleural fibrinolytic agents for pediatric empyema thoracis. Despite screening 2022 unique citations, no randomized controlled trials were found that met the eligibility criteria. Consequently, the review concludes that current evidence is insufficient to determine the optimal fibrinolytic agent for this condition.

Key findings

  • No randomized controlled trials were identified that met the eligibility criteria for evaluating fibrinolytic agents.
  • A total of 3110 records were identified, with 2022 unique citations screened.
  • The review highlights a significant gap in evidence for pediatric empyema thoracis management.

Why it matters

The lack of evidence-based guidelines for managing pediatric empyema thoracis complicates clinical decision-making. Understanding the efficacy and safety of treatment options is crucial for improving patient outcomes.

Source

PubMed · PMID 42616246Free full text on PubMed Central

Published in Indian Pediatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.